Overexpression of miR-184 disrupts the blood-brain barrier and larval locomotion. حسب Sravya Paluri (5475260)

Recognition of <i>F. novicida</i> strains by lysophagosomes and lysosomes in HeLa–FcγRII cells. حسب Dhandy Koesoemo Wardhana (21956781)

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …"

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …"

Inhibition of ferroptosis mitigated liver injury caused by <i>C. sinensis</i> infection. حسب Haoyang Zhang (1706815)

Fer-1 alleviated liver lesions caused by <i>C. sinensis.</i> حسب Haoyang Zhang (1706815)

Liver ferroptosis caused by <i>C. sinensis</i> infection in mice حسب Haoyang Zhang (1706815)

Inhibition of ferroptosis alleviated the expression of hepatic حسب Haoyang Zhang (1706815)

Microbial metabolic potentials categorized according to KEGG (A) level 1 and (B) level 2, representing control vs. stroke groups. حسب Duangnapa Roongpiboonsopit (12829198)

Inhibition of ferroptosis alleviated liver fibrosis caused by <i>C. sinensis.</i> حسب Haoyang Zhang (1706815)

Recognition of <i>F. novicida</i> strains by the mitochondria and Golgi complex in HeLa–FcγRII cells. حسب Dhandy Koesoemo Wardhana (21956781)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

(A) Changes of left ventricular ejection fraction over time in Roxadustat and ESAs groups. حسب Jie Liu (15128)